Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
23 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...